================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 15, 2004
TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-30975
(State of Formation) (Commission File Number)
911789357
(IRS Employer Identification Number)
12325 Emmet Street
Omaha, NE 68164
(Address of principal executive offices) (Zip Code)
(402) 452-5400
(Registrants' telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
================================================================================
Item 5. Other Events and Regulation FD Disclosure.
On January 15, 2004, the Company issued a press release announcing that
Nanogen Inc. and Transgenomic have entered into an agreement allowing
Transgenomic to distribute Nanogen's NanoChip(R) Molecular Biology Workstation
in selected Western European countries. A copy of the press release is filed
herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
99.1 Press Release, dated January 15, 2004, announcing that Nanogen Inc. and
Transgenomic have entered into an agreement allowing Transgenomic to
distribute Nanogen's NanoChip(R) Molecular Biology Workstation in selected
Western European countries.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
TRANSGENOMIC, INC.
By /s/ Michael J. Draper
------------------------------------------
Michael J. Draper, Chief Financial Officer
January 15, 2004
3